New data out of the AATS Annual Meeting identified significant potential for a new treatment strategy. 

Data from BENEFIT-HF, a new randomized study of CVRx's implantable Barostim device, could open up access to many more heart failure patients. 

When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.